FDA Inspection 1012179 — Ariad Pharmaceuticals
The FDA completed an inspection of Ariad Pharmaceuticals on May 31, 2017 in Cambridge, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 31, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cambridge, MA (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)